Patents by Inventor Byong Ha Kang

Byong Ha Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
    Publication number: 20230060304
    Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 2, 2023
    Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human Service
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
  • Monoclonal antibodies that bind human CD161
    Patent number: 11459389
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: October 4, 2022
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Karl Dane Wittrup, Kai Wucherpfennig, Byong Ha Kang, Nathan D. Mathewson
  • NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
    Publication number: 20210324053
    Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: October 21, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
  • MONOCLONAL ANTIBODIES THAT BIND HUMAN CD161 AND USES THEREOF
    Publication number: 20210122826
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 29, 2021
    Inventors: Karl Dane WITTRUP, Kai WUCHERPFENNIG, Byong Ha KANG, Nathan D. MATHEWSON
  • NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
    Publication number: 20200231658
    Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: February 10, 2020
    Publication date: July 23, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
  • Neutralizing antibodies to gp120 and their use
    Patent number: 10562960
    Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
  • NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
    Publication number: 20180298083
    Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: March 18, 2016
    Publication date: October 18, 2018
    Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human Services
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng